Rituximab news

Jaypirca reduced disease progression risk by 80% in CLL/SLL patients, showing promising safety and efficacy in a Phase 3 trial, with fewer adverse events compared to chemoimmunotherapy.

EPKINLY + R2 reduces disease progression risk by 79% in relapsed follicular lymphoma, with a 95% response rate. FDA-approved, it offers a new second-line treatment option.

EPKINLY + R² shows superior progression-free survival and response rates in Phase 3 trial for relapsed follicular lymphoma, with a consistent safety profile.